GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gwo Xi Stem Cell Applied Technology Co (ROCO:6704) » Definitions » Piotroski F-Score

Gwo Xi Stem Cell Applied Technology Co (ROCO:6704) Piotroski F-Score : 4 (As of Jan. 18, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Gwo Xi Stem Cell Applied Technology Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Gwo Xi Stem Cell Applied Technology Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Gwo Xi Stem Cell Applied Technology Co's Piotroski F-Score or its related term are showing as below:

ROCO:6704' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 4   Max: 4
Current: 4

During the past 6 years, the highest Piotroski F-Score of Gwo Xi Stem Cell Applied Technology Co was 4. The lowest was 3. And the median was 4.


Gwo Xi Stem Cell Applied Technology Co Piotroski F-Score Historical Data

The historical data trend for Gwo Xi Stem Cell Applied Technology Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gwo Xi Stem Cell Applied Technology Co Piotroski F-Score Chart

Gwo Xi Stem Cell Applied Technology Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial N/A 3.00 4.00 4.00 4.00

Gwo Xi Stem Cell Applied Technology Co Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 4.00 - 4.00 -

Competitive Comparison of Gwo Xi Stem Cell Applied Technology Co's Piotroski F-Score

For the Biotechnology subindustry, Gwo Xi Stem Cell Applied Technology Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gwo Xi Stem Cell Applied Technology Co's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gwo Xi Stem Cell Applied Technology Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Gwo Xi Stem Cell Applied Technology Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was NT$-88.1 Mil.
Cash Flow from Operations was NT$-4.9 Mil.
Revenue was NT$141.2 Mil.
Gross Profit was NT$96.8 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was (1044.891 + 1225.716) / 2 = NT$1135.3035 Mil.
Total Assets at the begining of this year (Dec22) was NT$1,044.9 Mil.
Long-Term Debt & Capital Lease Obligation was NT$366.0 Mil.
Total Current Assets was NT$424.4 Mil.
Total Current Liabilities was NT$115.5 Mil.
Net Income was NT$-112.1 Mil.

Revenue was NT$180.7 Mil.
Gross Profit was NT$154.8 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was (1087.81 + 1044.891) / 2 = NT$1066.3505 Mil.
Total Assets at the begining of last year (Dec21) was NT$1,087.8 Mil.
Long-Term Debt & Capital Lease Obligation was NT$427.9 Mil.
Total Current Assets was NT$200.8 Mil.
Total Current Liabilities was NT$106.7 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Gwo Xi Stem Cell Applied Technology Co's current Net Income (TTM) was -88.1. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Gwo Xi Stem Cell Applied Technology Co's current Cash Flow from Operations (TTM) was -4.9. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-88.089/1044.891
=-0.08430449

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-112.107/1087.81
=-0.10305752

Gwo Xi Stem Cell Applied Technology Co's return on assets of this year was -0.08430449. Gwo Xi Stem Cell Applied Technology Co's return on assets of last year was -0.10305752. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Gwo Xi Stem Cell Applied Technology Co's current Net Income (TTM) was -88.1. Gwo Xi Stem Cell Applied Technology Co's current Cash Flow from Operations (TTM) was -4.9. ==> -4.9 > -88.1 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=366.006/1135.3035
=0.32238604

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=427.908/1066.3505
=0.40128269

Gwo Xi Stem Cell Applied Technology Co's gearing of this year was 0.32238604. Gwo Xi Stem Cell Applied Technology Co's gearing of last year was 0.40128269. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=424.361/115.481
=3.67472571

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=200.779/106.665
=1.88233254

Gwo Xi Stem Cell Applied Technology Co's current ratio of this year was 3.67472571. Gwo Xi Stem Cell Applied Technology Co's current ratio of last year was 1.88233254. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Gwo Xi Stem Cell Applied Technology Co's number of shares in issue this year was 89.575. Gwo Xi Stem Cell Applied Technology Co's number of shares in issue last year was 85.42. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=96.774/141.176
=0.68548478

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=154.806/180.667
=0.8568582

Gwo Xi Stem Cell Applied Technology Co's gross margin of this year was 0.68548478. Gwo Xi Stem Cell Applied Technology Co's gross margin of last year was 0.8568582. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=141.176/1044.891
=0.13511074

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=180.667/1087.81
=0.16608323

Gwo Xi Stem Cell Applied Technology Co's asset turnover of this year was 0.13511074. Gwo Xi Stem Cell Applied Technology Co's asset turnover of last year was 0.16608323. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+1+0+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Gwo Xi Stem Cell Applied Technology Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Gwo Xi Stem Cell Applied Technology Co  (ROCO:6704) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Gwo Xi Stem Cell Applied Technology Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Gwo Xi Stem Cell Applied Technology Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Gwo Xi Stem Cell Applied Technology Co Business Description

Traded in Other Exchanges
N/A
Address
Guangming 6th Road, 8th Floor, No.243, Dong Section 1, Hsinchu County, Zhubei, TWN, 302041
Gwo Xi Stem Cell Applied Technology Co is committed to developing stem cell medicines that have the potential to help patients with unmet medical needs.

Gwo Xi Stem Cell Applied Technology Co Headlines

No Headlines